Phathom Pharmaceuticals Inc. announced the publication of new data from its Phase 3 pHalcon-NERD-301 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease $(NERD)$. The results, published in the American Journal of Gastroenterology, demonstrated that VOQUEZNA provided rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms. Patients treated with VOQUEZNA showed clinically meaningful increases in heartburn-free nights after the first dose, with these effects maintained through 24 weeks of treatment. The study found that, at week 4, mean percentages of heartburn-free nights were 59.9% and 56.4% for the 10 mg and 20 mg VOQUEZNA doses respectively, compared to 43.3% for placebo. The publication adds to the clinical evidence for VOQUEZNA in addressing nocturnal GERD symptoms.